🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Biliary Tract Carcinoma

A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations NCT05503797Phase 270 sites📍 Beverly Hills📍 San Francisco📍 Westwood, Los Angeles Fore Biotherapeutics · Tests: Plixorafenib AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064Phase 1, Phase 2120 sites📍 Los Angeles📍 Los Angeles📍 Whittier Daiichi Sankyo · Tests: Ifinatamab deruxtecan Efficacy of Fistulotomy for Biliary Cannulation NCT04037007NA1 site📍 Mexico City Coordinación de Investigación en Salud, Mexico · Tests: Fistulotomy - High experienced., Fistulotomy - Low experienced., Conventional (guidewire) cannulation- High experienced… A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) NCT06564623Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients NCT07673861NA1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Marsden360 ctDNA test and GTAB review Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688Phase 1, Phase 211 sites📍 San Antonio📍 Tyler📍 Spokane TiumBio Co., Ltd. · Tests: TU2218 + KEYTRUDA® (Pembrolizumab) Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III) NCT07161869n/a6 sites📍 Rotterdam📍 Amsterdam📍 Groningen Erasmus Medical Center · Tests: Registration of all findings during preoperative Endoscopic Ultrasound Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma NCT05874414Phase 1, Phase 211 sites📍 Los Angeles📍 Los Angeles📍 Orlando Genfit · Tests: GNS561 + Trametinib Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in Sohag Locality NCT07885800n/a1 site📍 Sohag Sohag University · Tests: histopathology of gall bladder Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer NCT07025174Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib, Oxaliplatin + 5-Fluorouracil/Leucovorin Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI NCT05172310Phase 11 site📍 Stockholm Karolinska University Hospital · Tests: 68Ga-FAPI-46, PET/CT Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients NCT07062263Phase 36 sites📍 Muzaffarpur📍 Mumbai📍 Bhubaneswar Tata Memorial Centre · Tests: Trastuzumab, Chemotherapy Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay) NCT04611867NA1 site📍 Herlev Inna Chen, MD · Tests: Supportive application with integrated weekly PRO Bile Omics for Diagnosing Indeterminate Biliary Strictures NCT07007832n/a1 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Endoscopic retrograde cholangiopancreatography Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818Phase 121 sites📍 Orange📍 Aurora📍 Layfayette I-Mab Biopharma US Limited · Tests: TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (… Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma NCT04993131NA1 site📍 Oslo Oslo University Hospital · Tests: Liver transplant San Raffaele Registry on Liver Cancer NCT07704489n/a1 site📍 Milan IRCCS San Raffaele Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers NCT06135896Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Tripegfilgrastim A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 NCT07186842Phase 1, Phase 218 sites📍 Denver📍 Orlando📍 Detroit BioNTech SE · Tests: BNT329, CA19-9-targeting monoclonal antibody Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer NCT07641036Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma NCT06175845NA9 sites📍 Berlin📍 Bonn📍 Chemnitz Universitätsklinikum Hamburg-Eppendorf · Tests: Intraductal biliary radiofrequency ablation Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma NCT07099547Phase 21 site📍 Hefei Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZG005, Tislelizumab, Gemcitabine, Cisplatin Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers NCT06001658Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Gemcitabine, Cisplatin, Pembrolizumab Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma NCT07235007NA8 sites📍 Aichi📍 Aichi📍 Aichi Aichi Medical University · Tests: Endobiliary Radiofrequency Ablation (EB-RFA), Plastic Biliary Stent A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6 Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas NCT07155525NA1 site📍 Minya Minia University · Tests: Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2), Standard(duct-to-mucosa) Pancreaticojejunost…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy